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Abstract  
The increasing use of the non-vitamin K oral anticoagulants 
during the recent years was associated with the need of 
development of targeted agents that could reverse the 
anticoagulative activity in cases of severe bleeding episodes or 
urgent high risk operations. Thus, several reversal agents are 
currently in development and the early results seem promising. 
Idarucizumab is a monoclonal antibody that can immediately 
and specifically reverse dabigatran action. Andexanet alfa is a 
recombinant modified factor Xa that can bind and reverse factor 
Xa inhibitors, including rivaroxaban, apixaban and edoxaban, 
and low molecular weight heparin. Aripazine is a universal 
reversal agent small molecule that can reverse the action of 
factor Xa inhibitors, unfractionated and low molecular weight 
heparin and possibly dabigatran. Currently, only idarucizumab 
has received approval from the United States Food and drug 
Administration for the reversal of the dabigatran. Rhythmos 
2016;11(3):70-72.   
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Abbreviations: AF = atrial fibrillation; dTT = dilute thrombin 
time; ECT = ecarin-clotting time; FDA = Food and Drug 
Administration; INR = International Normalized Ratio; LMWH 
= low molecular weight heparin; NOACs = non-vitamin K oral 
anticoagulants; VKAs = vitamin K antagonists   
Introduction  
For many years vitamin K antagonists (VKAs), such as 
warfarin and acenocoumarol, were the only clinically 
available anticoagulant agents for patients with atrial 
fibrillation (AF) or venous thromboembolism.1 During the 
last several years, the use of non-vitamin K oral 
anticoagulants (NOACs), both direct factor Xa and 
thrombin inhibitors, in clinical practice is constantly 
growing since their effectiveness and safety have been 
proved to be similar or better compared to VKAs.2 A major 
issue regarding the safety of NOACs is the reversal of their 
anticoagulation effect in emergency situations, such as a 
major bleeding event.3 Considering the non-availability of 
a quantitative measurement test for the extent of the 
anticoagulation effect of NOACs like the International 
Normalized Ratio (INR), there is great interest in 
developing novel agents that reverse the anticoagulative 
effect of NOACs.  In patients receiving NOACs only one 
clotting factor is blocked, either thrombin or factor Xa, 
although the plasma levels are within normal range. 
Currently only one specific reversal agent, idarucizumab, 
has been granted approval by the United States Food and 
Drug Administration (FDA), since there are data from 
clinical trials proving its effectiveness in the complete 
reversal of dabigatran action;4,5 while for andexanet alfa, 
FDA has accepted the Biologics License Application 
(BLA) for filing under a priority review. Andexanet alfa is 
designed to reverse the anticoagulant activity of factor Xa 
inhibitors (apixaban, rivaroxaban, and edoxaban). 
Moreover, Aripazine (Ciraparantag) is the agent which has 
been tested less in clinical trials compared to the other 
agents.6   
Idarucizumab  
Idarucizumab (Praxbind®, Boehringer Ingelheim, Inc., 
Ridgefield, CT, USA) is a humanized monoclonal 
antibody which binds both free and thrombin-bound 
dabigatran (Table 1). It has a high affinity for dabigatran 
about 350 times stronger than the affinity for thrombin and 
can reverse the anticoagulation effect at a 1:1 
stoichiometric ratio in vivo and in vitro.7 Idarucizumab is 
administrated by intravenous infusion, the half time is ~ 45 
min and finally the bound complex is eliminated mainly by 
renal excretion. Although idarucizumab has similar 
structure with thrombin, it does not have any 
prothrombotic activity.8 The estimation of its reversal 
effect can be obtained by measuring dilute thrombin time 
(dTT) and ecarin-clotting time (ECT), which are related 
with the unbound dabigatran concentration. In healthy 
volunteers who participated in a double blinded placebo 
controlled phase II trial, no serious adverse events have 
been reported.8 Only minor adverse events, such as 
erythema at the site of the drug administration, erythema 
and flu-like symptoms have been reported. The 
administration of 1, 2 and 4 g over 5 min resulted in a 
reduction of dTT by 74%, 94% and 98%, respectively. 
Dabigatran reversal was maintained over 72 hours with 2 
g or higher doses of idarucizumab.9  
Idarucizumab has been tested in a multicenter 
prospective single cohort study (RE-VERSE AD study) at 
a dose of 5 g in patients who had serious bleeding or 
required an urgent procedure.  The primary endpoint was 
the maximum percentage reversal effect of the dabigatran 
within 4 hours after the infusion of the idarucizumab as 
assessed by the dTT or ecarin clotting time.  An interim 
analysis was recently published which included 90 patients 
who received idarucizumab and the median time of the 
bleeding cessation was 11.4 hours in patients with serious 
bleeding. In patients who underwent an urgent procedure, 
intraoperative hemostasis was achieved in 92% of the 
cases. The mortality rate was reported at 20% with half of 
the occurred deaths due to the primary cause of 
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hospitalization. Only one thrombotic event occurred 
within 72 hours after idarucizumab administration in a 
patient in whom anticoagulant therapy had not been 
restarted.4 Data derived from 123 patients enrolled in the 
same study (RE-VERSE AD) were presented at the 
American College of Cardiology Congress on April 2016 
and did not differ significantly from those published 
previously regarding the effectiveness and safety rates.10 
Taking into account the results of the clinical trials of 
idarucizumab regarding its effectiveness and safety, in 
October 2015, the FDA approved its clinical use for cases 
requiring emergency reversal of dabigatran 
anticoagulation activity.11  
Andexanet alpha  
Andexanet alpha is a universal reversal agent that is 
designed to neutralize the anticoagulant effects of both 
direct and indirect factor Xa inhibitors (Table 1). It acts as 
a recombinant modified human Factor Xa decoy protein 
that binds to factor Xa inhibitors with high affinity and a 
1:1 stoichiometric ratio. Moreover, it binds both low 
molecular weight heparin (LMWH) and fondaparinux-
activated antithrombin III which act as indirect Xa 
inhibitors.12 Although andexanet alpha has similar 
properties to factor Xa, it has not been shown to have 
procoagulant catalytic activity. This is assessed by 
measurement of thrombin generation and anti–factor Xa 
activity which reflects the anticoagulant activity.13,14 In 
patients who were under rivaroxaban treatment with 20 mg 
daily for 6 days, the administration of 210 and 420 mg of 
andexanet alpha produced a reduction of factor Xa activity 
by 20% and 53% respectively without any serious adverse 
events. The discontinuation of andexanet alpha infusion 
resulted in normalization of factor Xa levels 2 hours later.15  
The clinical effectiveness of the drug was tested in the 
phase III ANNEXA trials which enrolled healthy subjects 
anticoagulated either with apixaban (ANNEXA-A) or 
rivaroxaban (ANNEXA-R).  Anti-factor Xa activity of 
apixaban and rivaroxaban was immediately reversed after 
a bolus injection of 400 mg and 800 mg, respectively. 
Thrombin generation was normalized without a rebound 
effect in the andexanet alfa group and there were no 
thrombotic events in these trials. The reversal effect was 
maintained for 2 hours after a bolus injection and for a 
longer duration with a continuous infusion of 4 mg/min for 
rivaroxaban and 8 mg/min for apixaban.5 An ongoing 
prospective open label trial is evaluating the hemostatic 
efficacy of andexanet alfa in patients receiving a factor Xa 
inhibitor who are experiencing an acute major bleed.16  
Aripazine (Ciraparantag/PER977)  
Aripazine is a synthetic molecule that can bind and 
reverse the action of unfractionated and low molecular 
weight heparins, direct factor Xa inhibitors and direct 
thrombin inhibitors in a dose-dependent manner 6 (Table 
1). In a preliminary study which enrolled 80 healthy 
subjects, who received orally 60 mg of edoxaban, the 
infusion of 100-300 mg of aripazine restored hemostasis 
within 10-30 minutes with a sustained efficacy for 24 
hours. In the placebo arm of the study the clotting time 
reached baseline levels after 12–15 hours.6 Data from large 
scale clinical trials are scarce and moreover the exact 
mechanism of action is not yet completely understood. 
Phase III clinical trials especially with edoxaban are 
underway.17  
Conclusion   
The development of specific antidotes for NOAC 
reversal augments the safety for patients who suffer from 
serious bleeding or undergo an urgent operation related to 
high bleeding risk.18 The fact is that most bleeding 
episodes can be managed by interruption of NOAC therapy 
and/or supportive measures. Currently, only idarucizumab 
has been approved by FDA targeting dabigatran action 
reversal but in the near future more agents with a universal 
action are likely to receive approval. The high cost of those 
reversal agents requires a thorough assessment in order to 
select eligible patients who will benefit from the use of 
these drugs.  
Table 1. Data regarding the effectiveness and the safety 
of the three reversal agents  
Drug Mechanism of action 
Indicated 
dose 
Time to 
reversal 
Possible 
adverse 
events 
Idarucizumab 
Binds free & 
thrombin-
bound 
dabigatran 
5 g (2.5 g x 
2) i.v. bolus 
within 15 
min 
dTT & eCT 
normalize after 
first infusion  
Median time to 
bleeding 
cessation 11.4 h 
Skin 
irritation, 
headache 
No pro-
thrombotic 
effect 
Andexanet 
alpha 
Binds factor 
Xa inhibitors: 
apixaban, 
rivaroxaban 
& edoxaban 
400 mg iv 
bolus ± 2 h 
i.v. (4 mg/ 
min) 
Mean 94±2% 
decrease in anti 
fXa activity 
after 2-5min 
Reversal 
activity persists 
1–2 hours 
No 
prothrombo
tic effect 
Aripazine 
(Ciraparantag) 
Universal 
reversal 
agent, binds 
direct 
thrombin & 
Xa inhibitors 
& unfractio-
nated & 
LMW heparin 
100 mg 
single i.v 
dose 
30 min: 
restoration of 
wBCT & mean  
fibrin diameter 
Facial 
flushing, 
dysgeusia 
(scarce 
data) 
 
No 
prothrombo
tic effect 
dTT = dilute thrombin time; eCT = ecarin clotting time; fXa = factor 
Xa; LMWH = low molecular weight heparin; wBCT = whole blood 
clotting time 
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